1. Home
  2. ALVOW vs CCIA Comparison

ALVOW vs CCIA Comparison

Compare ALVOW & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALVOW
  • CCIA
  • Stock Information
  • Founded
  • ALVOW 2013
  • CCIA N/A
  • Country
  • ALVOW Luxembourg
  • CCIA
  • Employees
  • ALVOW N/A
  • CCIA N/A
  • Industry
  • ALVOW Biotechnology: Biological Products (No Diagnostic Substances)
  • CCIA
  • Sector
  • ALVOW Health Care
  • CCIA
  • Exchange
  • ALVOW Nasdaq
  • CCIA Nasdaq
  • Market Cap
  • ALVOW N/A
  • CCIA N/A
  • IPO Year
  • ALVOW N/A
  • CCIA 2023
  • Fundamental
  • Price
  • ALVOW $2.45
  • CCIA $26.21
  • Analyst Decision
  • ALVOW
  • CCIA
  • Analyst Count
  • ALVOW 0
  • CCIA 0
  • Target Price
  • ALVOW N/A
  • CCIA N/A
  • AVG Volume (30 Days)
  • ALVOW 15.0K
  • CCIA N/A
  • Earning Date
  • ALVOW 02-27-2025
  • CCIA N/A
  • Dividend Yield
  • ALVOW N/A
  • CCIA N/A
  • EPS Growth
  • ALVOW N/A
  • CCIA N/A
  • EPS
  • ALVOW N/A
  • CCIA N/A
  • Revenue
  • ALVOW $393,919,000.00
  • CCIA N/A
  • Revenue This Year
  • ALVOW N/A
  • CCIA N/A
  • Revenue Next Year
  • ALVOW N/A
  • CCIA N/A
  • P/E Ratio
  • ALVOW N/A
  • CCIA N/A
  • Revenue Growth
  • ALVOW 517.92
  • CCIA N/A
  • 52 Week Low
  • ALVOW $2.33
  • CCIA N/A
  • 52 Week High
  • ALVOW $2.33
  • CCIA N/A
  • Technical
  • Relative Strength Index (RSI)
  • ALVOW N/A
  • CCIA 50.19
  • Support Level
  • ALVOW N/A
  • CCIA $26.14
  • Resistance Level
  • ALVOW N/A
  • CCIA $26.50
  • Average True Range (ATR)
  • ALVOW 0.00
  • CCIA 0.13
  • MACD
  • ALVOW 0.00
  • CCIA -0.04
  • Stochastic Oscillator
  • ALVOW 0.00
  • CCIA 12.18

About ALVOW Alvotech Warrant

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: